Dexmedetomidine in asthma

Comparison clinical efficacy of IV Dexmedetomidine plus nebulized salbutamol in contrast whit nebulized salbutamol alone in management of acute asthma attack

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20131118015446N14

Enrollment

Registered

2018-06-01

Start date

2018-04-21

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Asthma

Interventions

The intervention group will receive 0.5 mg ipratropium nubulized (repeated up to 3 doses in every 20 minutes), 5 mg Albuterol inhalation and Prednisolon at the beginning (zero time point). Also, 0.5 m

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: All of patients whit Asthma attack Age between 18-55 years old

Exclusion criteria

Exclusion criteria: Pregnancy Age under 18 and more than 55 years old Smoking more than 10 pack/year Other chronic deaseas

Design outcomes

Primary

Measure	Time frame
PEFR. Timepoint: 0, 30, 60 minutes after treatmen. Method of measurement: Spirometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHassan Motamed

Ahvaz University of Medical Sciences

motamed-h@ajums.ac.ir+98 61 3374 3009

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026